Myasthenia Gravis, Generalized Clinical Trial
Official title:
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study of Telitacicept in Patients With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in the treatment of patients with generalized myasthenia gravis.
This study consists of a screening period, a double-blind treatment period (part A) and an open-label treatment period (part B). After screening, eligible subjects will be randomized in a 1: 1 ratio to receive either subcutaneous Telitacicept 240 mg or placebo once a week for 24 doses (part A). Completing part A, subjects will automatically enter part B. In part B, all subjects will receive weekly subcutaneous Telitacicept 240 mg for 24 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02565576 -
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
|
Phase 2 | |
| Completed |
NCT04115293 -
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT04224506 -
A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
|
||
| Recruiting |
NCT04431895 -
Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study
|
Early Phase 1 | |
| Recruiting |
NCT05067348 -
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
|
Phase 2 | |
| Withdrawn |
NCT03165435 -
A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05214612 -
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
|
||
| Recruiting |
NCT05868837 -
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
|
Phase 3 | |
| Recruiting |
NCT06282159 -
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
|
Phase 2 | |
| Recruiting |
NCT04146051 -
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
|
Phase 2 | |
| Completed |
NCT03759366 -
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
|
Phase 3 | |
| Completed |
NCT02473952 -
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
|
Phase 2 | |
| Completed |
NCT00683969 -
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis
|
Phase 3 | |
| Completed |
NCT03304054 -
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
|
Phase 3 | |
| Recruiting |
NCT05716035 -
Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
|
Phase 2/Phase 3 |